𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Race, biochemical disease recurrence, and prostate–specific antigen doubling time after radical prostatectomy : Results from the SEARCH database

✍ Scribed by Robert J. Hamilton; William J. Aronson; Joseph C. Presti Jr; Martha K. Terris; Christopher J. Kane; Christopher L. Amling; Stephen J. Freedland


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
118 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND.

Whether black men are at increased risk for biochemical disease recurrence after radical prostatectomy (RP) is debatable. Once black men have developed disease recurrence, it is unknown whether they have more aggressive disease than white men. To address this issue, the authors examined racial differences in pathologic features, time to disease recurrence, and prostate–specific antigen (PSA) doubling time (PSADT) among a cohort of patients treated with RP.

METHODS.

The authors analyzed 953 white and 659 black men who were treated at 5 medical centers comprising the Shared Equal Access Regional Cancer Hospital (SEARCH) Database between 1988 and 2006. The association between race, adverse pathologic features, and biochemical disease recurrence was examined. Among those patients who developed disease recurrence, time to recurrence and PSADT were compared between the races.

RESULTS.

Black men were on average 2.1 years younger (P < .001) and had higher median preoperative PSA levels (7.6 ng/mL vs 7.0 ng/mL; P < .001), yet presented with a lower clinical stage of disease (T1: 62% vs 44%; P < .001) and similar biopsy Gleason scores (P = .59). After adjusting for multiple clinical characteristics, black men were found to be as likely as white men to have adverse pathologic features (Gleason score ≥7, positive surgical margins, and seminal vesicle invasion) in the RP specimen and were less likely to have extracapsular extension (P = .03). Black men were more likely to have a biochemical disease recurrence (hazards ratio [HR] of 1.28; 95% confidence interval [95% CI, 1.07–1.54 [P = .006]). This increased risk was reduced slightly after adjustment for multiple clinical and pathologic features, and no longer achieved statistical significance (HR of 1.19; 95% CI, 0.97–1.45 [P = .09]). Among men who developed disease recurrence, the median PSADT was found to be similar among black men (17.0 months) and white men (14.6 months) (P = .26).

CONCLUSIONS.

Despite presenting with earlier clinical stage and similar pathologic features at RP, black men were found to be at a slightly increased risk for biochemical disease recurrence. However, these recurrences appear to be no more aggressive than those found in white men. Cancer 2007;110:2202–9. © 2007 American Cancer Society.


📜 SIMILAR VOLUMES


Race, biochemical disease recurrence, an
✍ Isaac Powell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

In their study in the current issue of __Cancer__, Hamilton et al. attempt to resolve conflicting data regarding prostate cancer and racial outcomes. The most interesting findings include a significantly younger population of black men with higher prostate–specific antigen levels, similar tumor grad

The percentage of prostate needle biopsy
✍ Stephen J. Freedland; William J. Aronson; Martha K. Terris; Christopher J. Kane; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Background: The authors previously found that, although the total percentage of prostate needle biopsy cores with carcinoma was a significant predictor of prostate specific antigen (psa) failure among men undergoing radical prostatectomy (rp), there was a trend toward a lower risk of recurrence

Patient reported incontinence after radi
✍ Andrew C. Peterson; Yongmei Chen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Abstract ## Aims The reported incidence of urinary incontinence (UI) after radical prostatectomy (RP) ranges from 2.5 to 87%. We reviewed data from the Center for Prostate Disease Research (CPDR) to determine the incidence of patient reported UI after RP (postRPUI) and establish risk factors fo